Abstract
This case report describes an exacerbation of AIDS-associated Kaposi sarcoma (KS) in the setting of iatrogenic Cushing syndrome caused by an interaction between ritonavir-boosted atazanavir and fluticasone. Discontinuation of fluticasone resulted in resolution of the cutaneous KS. Clinicians should be aware of this potential drug-drug interaction that can result in increased corticosteroid levels. Inhaled corticosteroids should be used cautiously in persons with HIV/AIDS who have a history of KS and are being treated with a boosted atazanavir regimen because this can potentially exacerbate KS.
MeSH terms
-
Androstadienes / adverse effects*
-
Anti-Inflammatory Agents / adverse effects*
-
Atazanavir Sulfate
-
Cushing Syndrome* / complications
-
Cushing Syndrome* / drug therapy
-
Drug Interactions
-
Fluticasone
-
HIV Infections* / complications
-
HIV Infections* / drug therapy
-
HIV Protease Inhibitors / adverse effects*
-
Humans
-
Iatrogenic Disease
-
Male
-
Middle Aged
-
Oligopeptides / adverse effects
-
Pyridines / adverse effects
-
Ritonavir / adverse effects
-
Sarcoma, Kaposi / physiopathology*
Substances
-
Androstadienes
-
Anti-Inflammatory Agents
-
HIV Protease Inhibitors
-
Oligopeptides
-
Pyridines
-
Atazanavir Sulfate
-
Fluticasone
-
Ritonavir